Checkpoint Responses in Cancer Therapy
Extensive research has uncovered a set of molecular surveillance mechanisms – commonly called "checkpoints" – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now prom...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Totowa, NJ :
Humana Press,
2008.
|
| Σειρά: | Cancer Drug Discovery and Development•
|
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- RB-Pathway
- Targeting the p53/MDM2 Pathway for Cancer Therapy
- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer
- Targeting ATM/ATR in the DNA Damage Checkpoint
- Compounds that Abrogate the G2 Checkpoint
- CDK Inhibitors as Anticancer Agents
- CHFR as a Potential Anticancer Target
- Antimicrotubule Agents
- Kinesin Motor Inhibitors as Effective Anticancer Drugs
- Targeting the Spindle Checkpoint in Cancer Chemotherapy
- Antiproliferation Inhibitors Targeting Aurora Kinases
- Plks as Novel Targets for Cancer Drug Design
- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?.
